Lilly’s Emgality wins first nod for migraine prevention
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
Read More
Tag: REGAIN
Lilly files anti-CGRP drug for migraine
US regulators have accepted for review Eli Lilly’s investigational non-opioid pain drug galcanezumab for the prevention of migraine.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
